Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 10/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | ASPH | Q12797 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29488317 | 0.85 | P4HTM (0.53) | P4HTMALDH1A1P4HA1MIFKDM4E | |
| SCHEMBL2300999 | 0.85 | P4HTM (0.53) | P4HTMALDH1A1P4HA1MIFKDM4E | |
| SCHEMBL10329128 | 0.82 | P4HTM (0.50) | P4HTMALDH1A1P4HA1MIFKDM4E | |
| SCHEMBL17162305 | 0.82 | P4HTM (0.54) | P4HTMALDH1A1TSHRP4HA1MIF | |
| SCHEMBL1974946 | 0.80 | P4HTM (0.52) | P4HTMALDH1A1TSHRP4HA1MIF | |
| SCHEMBL17162444 | 0.78 | P4HTM (0.50) | P4HTMALDH1A1TSHRP4HA1MIF | |
| SCHEMBL11894305 | 0.78 | P4HTM (0.53) | P4HTMALDH1A1TSHRP4HA1MIF | |
| SCHEMBL287558 | 0.78 | P4HTM (0.53) | P4HTMALDH1A1P4HA1MIFKDM4E | |
| SCHEMBL10680849 | 0.76 | TRPV1 (0.37) | ALDH1A1TSHRHSD17B10L3MBTL1TRPV1 | |
| SCHEMBL1748982 | 0.75 | P4HTM (0.50) | P4HTMALDH1A1P4HA1MIFKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170267673-A1 | CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170267673-A1 | CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-9550762-B2 | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use | AMGEN, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550762-B2 | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use | AMGEN, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| WO-2016022724-A1 | CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267673-A1 | CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | BACE1, BACE2, APP | P4HTM 1593/4885ALDH1A1 1149/4885TSHR 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.